Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective
Maja Pizevska, Jaspal Kaeda, Enrico Fritsche, Hisham Elazaly, Petra Reinke, Leila Amini
Berlin Institute of Health at Charité - Universitätsmedizin Berlin Charité – Universitätsmedizin Berlin
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Advanced Therapy Medicinal Products (ATMPs) comprising cell, gene, and tissue-engineered therapies have demonstrated enormous therapeutic benefits. However, their development is complex to be managed efficiently within currently existing regulatory frameworks. Legislation and regulation requirements for ATMPs must strike a balance between the patient safety while promoting innovations to optimize exploitation of these novel therapeutics. This paradox highlights the importance of on-going dynamic dialogue between all stakeholders and regulatory science to facilitate the development of pragmatic ATMP regulatory guidelines.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Biomedical Ethics and Regulation
Healthcare Regulation · Pharmaceutical Economics and Policy
参考文献 30
此处列出前 3 条
引用本文 67
按被引量排序,此处列出前 3 条